ESMO and WCLC: Latest developments in EGFR mutated NSCLC
18 Oct 2024
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in head and neck cancer treatment in India
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Advancements in paediatric Acute lymphoblastic leukemia management
Enhancing head and neck oncology: Key insights from the conference
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing 1st line TKI Wisely in patients with CML
Choosing Wisely in endometrial & cervix cancers: Medical therapy